About the Journal

This page provides detailed information about the journal’s scope, policies, publishing practices, and governance.

About

Cancer Biome and Targeted Therapy (CBTT) is a peer-reviewed, open-access journal dedicated to understanding cancer as a dynamic biological ecosystem and translating these insights into precision and targeted therapeutic strategies.

The journal focuses on interactions among tumor cells, immune and stromal cells, microbial communities, metabolic networks, and therapeutic interventions that shape cancer progression, immune regulation, metastasis, treatment response, and therapeutic resistance.

CBTT publishes original research, reviews, and translational studies focused on cancer biology, the tumor microenvironment, cancer immunology, microbiome research, molecular oncology, precision oncology, and targeted therapeutics.

Aims and Scope

Cancer Biome and Targeted Therapy (CBTT) publishes high-quality original research, reviews, and translational studies at the intersection of cancer biology, tumor ecosystems, immunology, microbiology, and precision oncology.

The journal views cancer as a dynamic biological ecosystem in which tumor cells interact with immune and stromal populations, microbial communities, metabolic networks, extracellular vesicles, and other components of the tumor microenvironment. CBTT seeks to advance understanding of how these interactions regulate tumor development, metastasis, immune surveillance, therapeutic response, and resistance.

The journal particularly welcomes studies that connect mechanistic cancer biology with therapeutic vulnerability, biomarker development, treatment response, and clinical translation.

Areas of Interest

  • Tumor Ecosystems and Microenvironment: tumor–stroma interactions, cancer-associated fibroblasts, tumor-associated macrophages, myeloid and lymphoid populations, extracellular matrix, hypoxia, angiogenesis, metastasis, and tumor immune microenvironments.

  • Cancer Immunology and Immune Metabolism: tumor–immune interactions, immune checkpoints, cellular metabolism, immunosuppression, immune-cell function, immunotherapy response and resistance, and strategies for remodeling the tumor immune ecosystem.

  • Cancer Microbiome and Microbial Interactions: tumor-associated and gut microbiomes, bacterial, fungal, viral, and other microbial influences on carcinogenesis, tumor progression, immunity, metabolism, therapeutic response, and resistance.

  • Molecular Mechanisms and Therapeutic Resistance: oncogenic signaling, epigenetic regulation, cell-death pathways, metabolic vulnerabilities, epithelial–mesenchymal transition, DNA-damage responses, drug resistance, and mechanisms underlying treatment failure.

  • Precision, Targeted, and Translational Oncology: targeted therapies, antibody–drug conjugates, cellular therapies, immunotherapies, gene and genome editing, patient-derived organoids, cancer models, biomarkers, computational approaches, drug screening, and precision treatment strategies.

CBTT welcomes interdisciplinary studies integrating molecular, cellular, computational, microbial, immunological, and translational approaches to address clinically relevant questions in cancer.

Co-Editors-in-Chief:

Antoine Italiano, MD, PhD; Ubaldo Martinez-Outschoorn, MD, PhD; Peng Huang, PhD.
Co-Editors-in-Chief and Editorial Board members' contact information is listed on the Editorial Board Team

Cancer Biome and Targeted Therapy follows recognized standards of publication ethics, research integrity, and open-access publishing. The journal follows the Core Practices of the Committee on Publication Ethics (COPE) and maintains policies consistent with applicable open-access publishing standards. The journal maintains editorial independence and applies its editorial and peer-review policies consistently to all submissions.

Mission Statement

CBTT is committed to advancing a systems-level understanding of cancer by exploring the biological, immunological, microbial, and therapeutic dimensions of the tumor ecosystem. Our mission is to provide an open-access platform for high-quality, peer-reviewed research that uncovers how the complex interplay between tumors and their surrounding ecosystems influences disease behavior, therapeutic response, and clinical translation.

Publication Ethics and Editorial Independence

CBTT follows recognized standards of publication ethics and research integrity, including the principles and Core Practices of the Committee on Publication Ethics (COPE). The journal maintains editorial independence and applies its peer-review, authorship, conflict-of-interest, research-integrity, correction, retraction, and appeals policies consistently to all submissions.

Article Processing Charge (APC)

Cancer Biome and Targeted Therapy does not charge submission fees, page charges, color, or other publication fees or article processing charges (APCs). All accepted articles are published open access, at no cost to authors. 

Instructions for authors

Detailed information on manuscript preparation, article types, submission requirements, peer review procedures, publication policies, and ethical standards is provided in the Instructions for Authors. View Instructions for Authors

Open Access

Under the open-access model, Cancer Biome and Targeted Therapy does not impose embargoes or subscription restrictions. All articles are freely accessible immediately upon publication, giving readers instant, unrestricted access to the content. All articles are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). https://creativecommons.org/licenses/by/4.0/.

Copyright

Authors retain copyright of their work and grant the journal the right of first publication under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publishing Frequency

Cancer Biome and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes four regular issues per year, scheduled for February, May, August, and November.

Language

English

About the Publisher 

Cancer Biome and Targeted Therapy is published by GCINC Press, the scholarly publishing imprint of Global Consulting Inc., a U.S. Corporation. GCINC Press is not a separate legal entity from Global Consulting Inc.

Registered Address:
Global Consulting Inc. / GCINC Press
522 W Riverside Ave, Suite N
Spokane, WA 99201
United States

Publisher Contact Email:
submissions@cancerbiometherapy.com

 

Publishing Platform and Digital Preservation

Cancer Biome and Targeted Therapy is hosted on the Open Journal Systems (OJS) platform, developed and maintained by the Public Knowledge Project (PKP). The journal maintains regular backups and supports digital preservation through the PKP Preservation Network (PKP PN) and LOCKSS-based preservation mechanisms. The journal takes reasonable measures to support platform stability, data security, privacy, and long-term accessibility. Technical infrastructure and certain services may be provided by third-party providers.

Metadata Exposure and Repository Interoperability

In addition to digital preservation, Cancer Biome and Targeted Therapy supports standardized metadata dissemination through the Open Archives Initiative Protocol for Metadata Harvesting (OAI-PMH). Article-level metadata are available for harvesting by libraries, institutional repositories, and indexing services, facilitating discovery, citation, and long-term access to published content.

Self-Archiving Policy (For Accepted Manuscripts):

Authors are permitted and encouraged to post the accepted version (postprint) of their manuscript, after peer review but before final typesetting, in personal repositories, institutional archives, or recognized preprint servers. This policy applies to the accepted manuscript version and does not restrict the sharing of links to the final published version of record.

To preserve the integrity of the published record, authors should:

  • Clearly label the version as "Accepted Manuscript."
  • Include the DOI and citation to the final published version once available
  • Do not share the formatted publisher PDF without prior permission

This policy supports author visibility, compliance with funder requirements, and the broader goals of open science.